American Society of Hematology

New ASH 2021 data for the stem cell transplant therapy suggest it has a durable and safe benefit for adults with severe disease.

Investigators added improvements were needed regarding access to complete diagnostic evaluation among Black patients, citing disparities in care.

Data show the majority of patients who initiated crizanlizumab remained on therapy, while a third of patients saw barriers including insurance coverage.

New research on the preclinical product TALGlobin01 reveals the potential impact that gene therapy can have on the future of sickle cell disease treatment.

New cohort analysis suggest a heightened risk of atrial fibrillation may be worsening patients' life expectancies.

Investigators aimed to improve lentiviral vectors to boost therapeutic β-like globin levels without increasing the mutagenic vector load in hematopoietic stem/progenitor cells.

New data for the Rocket Pharmaceutical gene therapy candidate show durable benefit in patients 6 months out from transplant.

The global biopharmaceutical company released research data on rozanolixizumab and zilucoplan at the 2021 ASH annual meeting and exposition.

An international assessment shows many patients are wary of emergency rooms, and clinicians want more diverse therapies.

Data show 12 of 25 strokes (48%) in a cohort of children did not met the definition of typical stroke related to sickle cell cerebral vasculopathy.

Data from phase 1 and phase 2 of the Alta study was presented at ASH this weekend.

Defined roles and research-informed recommendations are lacking for clinicians navigating birth control with females with sickle cell.

Investigators suggested this approach will allow for comprehensive mapping of the genomic landscape and clonal evolution of stem cells in sickle cell patients

Patients with sickle cell disease often suffer from acute kidney injuries and chronic kidney disease.

Shaji Kumar, MD, presents final Phase 3 data of the BELLINI trial at the ASH 2021 conference.

An ongoing assessment of caregivers considering hydroxyurea initiation for children with sickle cell disease provides a look into how such families are handling telemedicine and the pandemic.

Data show the average maximum cortical capillary RBC velocity is significantly greater in sickle cell mice compared to controls.

New ASH 2021 data shows how guidance is still lacking for clinicians responsible for addressing contraception with women with sickle cell disease.

Children with sickle cell disease have the opportunity to learn about STEM concepts in the context of their own condition.

A continued conversation on the intricate, patient-centric benefits of care with the subcutaneous agent.

The UCSF hematologist discusses the growing portfolio for the sickle cell therapy after ASH 2020.

New ASH data demonstrates that RUDAS and MoCA scores are associated with highest level of education.

Luspatercept added to best supportive care reduced transfusion burden while TranQol and SF-36 HRQoL scores were maintained through Week 48.

A Phase I study reports on the safety and potential efficacy of lintuzumab Ac225 plus CLAG-M for relapsed/refractory acute myeloid leukemia.

The historic phase 3 HOPE-B trial shows all but 1 treated patient discontinued prophylaxis after a single dose of etranacogene deaparvovec.

The second process of ARU-1801 in a new patient resulted in up to 4 times greater engraftment of transduced hematopoietic stem cells and progenitors at 6 months.

An interview with a Janssen expert on the growing portfolio and newest data for daratumumab.

The sickle cell disease subtype is associated with increased risk among patients as young as 2 years old.

In data presented at ASH 2020, FT-4204 shows early potential in being safe, efficacious treatment for sickle cell disease.

The ongoing phase I study also demonstrates that the drug is associated with an increase in Hb from baseline with a concomitant decrease in hemolytic markers.